GANGWAL



Bringing Life To Formulations

ABOUT US

Gangwal Healthcare is a trusted solutions provider and manufacturer dedicated to advancing healthcare through innovative research and cutting-edge technology. We are committed to addressing complex healthcare challenges with novel formulations designed to improve quality of life.

As new health issues emerge daily, Gangwal Healthcare leverages its extensive expertise, working closely with industry leaders in pharmaceuticals and nutraceuticals to create optimal solutions. Our process begins with a deep understanding of your unique needs and insights, followed by sourcing premium raw materials. These are then seamlessly integrated with our advanced technologies and processes, delivering high-quality products that simplify complexities and meet

QUALITY CERTIFICATES

Manufacturing Facilities






02 FACTORY

PHARMACEUTICAL

01 FACTORY

NUTRCEUTICAL

01 FACTORY

COSMECEUTICAL

MPRESSOL™ Mannitol

DILUENT / FILLER

PRODUCT OVERVIEW

Versatile Excipient for Pharmaceutical Excellence

Mannitol, a naturally occurring polyol, is a cornerstone in pharmaceutical formulations. It functions as an inert filler, diluent, and sweetening agent in a diverse range of dosage forms, from tablets to powders.

KEY FEATURES

Non-Hygroscopic Stability

Zero moisture uptake at high humidity (~80% RH), protecting moisture-sensitive APIs from degradation.

Chemical Inertness

Highly stable and inert with APIs, preventing Maillard reactions or other incompatibilities.

Water Solubility & Wetting

Freely soluble (~18–20% w/v at 20°C), aiding rapid disintegration and drug release.

Organoleptic Benefits

Mild sweet taste and cooling sensation improve mouthfeel for chewable and orally disintegrating forms.

REGULATORY COMPLIANCE

• USP-NF • BP • IP • EP

Grades	Particle Size
MPRESSOL™	–
MPRESSOL™ – 25	25µ

MPRESSOL™ 100

- Retained on 100# - NMT 35%
- Retained on 200# - NLT 70%

MPRESSOL™ 200

- Retained on 50# - NMT 10%
- Retained on 100# - NLT 45%
- Retained on 400# - NLT 90%

Complexol-HP®

Hydroxypropyl Betadex

SOLUBILIZER / STABILIZER

PRODUCT OVERVIEW

Hydroxypropyl Beta Cyclodextrin (HP-□-CD) is a water-soluble derivative of Beta Cyclodextrin, widely used as a complexing agent in pharmaceutical formulations. It enhances the solubility, stability, and bioavailability of poorly soluble drugs, making it an essential excipient for modern drug delivery systems.

KEY FEATURES

Improved Solubility
Forms inclusion complexes with hydrophobic drugs, significantly enhancing solubility.

Enhanced Stability
Protects sensitive APIs from light, heat, & oxidation.

Biocompatibility
Non-toxic and non-irritating, suitable for parenteral, oral, and topical applications.

Wide pH Range
Effective across a broad pH range (3–12).

Low Hemolytic Activity
Safer than other cyclodextrin derivatives for intravenous use.

PACKED SIZE
20 Kg / 25 Kg

Grades	Molar Substitution
Low	0.45 - 0.65
Medium	0.5 - 0.75
High	0.76 - 1.2

REGULATORY COMPLIANCE
• USP-NF • BP • EP

Complexol-B®

Betacyclodextrin

SOLUBILIZER / STABILIZER

PRODUCT OVERVIEW

Beta Cyclodextrin (BCD) is a cyclic oligosaccharide composed of 7 glucose units linked by □-1,4 glycosidic bonds. It is widely used in pharmaceutical, food, and cosmetic industries for its ability to form inclusion complexes with hydrophobic molecules. This enhances solubility, stability, and bioavailability, making it a versatile excipient in product formulations.

KEY FEATURES

Improved Solubility

Encapsulates poorly water-soluble compounds, making them highly soluble in aqueous solutions.

Enhanced Stability

Protects sensitive APIs from light, heat, & oxidation.

Odor and Taste Masking

Effectively masks unpleasant odors and tastes in formulations.

Biocompatible and Safe

Non-toxic, non-immunogenic, and suitable for use in a wide range of applications.

Environmentally Friendly

Biodegradable and sourced from renewable materials

PACKED SIZE

25 Kg

APPLICATIONS

Solubilizer

Increases solubility of hydrophobic APIs.

Stabilizer

Extends shelf life by protecting APIs from environmental factors.

Taste Masking

Used in orally administered Dosage form like syrups, lozenges, tablets, capsules, etc.

REGULATORY COMPLIANCE

• USP-NF • BP • EP

TYLUX
Tyloxapol

SOLUBILIZER / STABILIZER

PRODUCT OVERVIEW

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It serves as a versatile pharmaceutical excipient with unique properties that enhance drug formulations.

KEY FEATURES

Superior Wetting & Emulsification

Tyloxapol reduces surface tension, improving dispersion of active ingredients for stable emulsions and suspensions.

Bioavailability Booster

Significantly enhances the solubility of poorly soluble drugs, facilitating hydrophobic API formulation for efficient delivery.

Enhanced Formulation Stability

Polymeric structure stabilizes emulsions, prevents particle aggregation, and protects proteins/enzymes in solution.

Broad Compatibility

Its non-ionic and inert nature ensures compatibility with diverse ingredients, suitable for sensitive applications with a low-irritation profile.

REGULATORY COMPLIANCE

- USP-NF

Sorbiplast®

Plasticizer For Soft Gel Capsule

PLASTICIZER

PRODUCT OVERVIEW

Sorbitol Sorbitan Solution

D-Sorbitol (NLT 25%) + 1,4-Sorbitan (NLT 15%) + Water (NMT 31.5%)

Sorbitol Sorbitan Solution is not just a plasticizer—it is a process enabler that enhances throughput, reduces defects, and ensures consistent capsule quality, aligning directly with operational excellence goals.

KEY FEATURES

Stable Plasticizer Composition

- Fixed sorbitol-to-sorbitan ratio ensures consistent plasticizing action
- Reduces variability in shell elasticity and flexibility

Uniform Gelatin Mass Rheology

- Delivers predictable viscosity and gel strength in each batch
- Supports homogeneous mixing and film casting

Controlled Moisture Activity

- Maintains steady water activity without over-softening or drying
- Minimizes impact of humidity variations during production

Reduced Plasticizer Migration

- Lowers material waste, consistent film properties.
- Reduces indirect cost of rework, reprocessing, and machine wear and tear.
- Longer capsule shelf life reduces product returns and repackaging costs.

Resistance to Cross-Linking & Aging

- Lower risk of reactive degradation or hard shell formation over time
- Ensures long-term physical and dissolution stability

Enhanced Process Repeatability

- Consistent thermal and rheological behaviour supports reproducible process parameters
- Improves sealing, drying, and shell thickness control across batches

PACKED SIZE

25 Kg / 50 Kg / 250 Kg

REGULATORY COMPLIANCE

• USP • BP • EP

LUBRIORB™

SODIUM STEARYL FUMARATE

LUBRICANT

PRODUCT OVERVIEW



KEY FEATURES

High Compressibility
Maintains tablet hardness and integrity under high compression forces.

Reduced Lubrication Sensitivity
Prevents over-lubrication, which can negatively impact dissolution profiles.

Improved Dissolution and Bioavailability
Particularly beneficial for poorly soluble drugs, ensuring faster release.

Compatibility with APIs and Excipients
Compatible with a wide range of active pharmaceutical ingredients (APIs) & excipients.

Low Hydrophobicity
Avoids retardation of drug release compared to other hydrophobic lubricants.

BENEFITS OVER MAGNESIUM STEARATE

Minimized Delayed Drug Release:
Ensures consistent dissolution profiles.

Improved Flow Properties:
Better powder flow during production.

Reduced Risk of Drug-Excipient Interaction:
Ensures drug stability over time.

Grades	Surface Area
Lubriorb	1 to 4 ms/g
Lubriorb M	1.20 to 2 ms/g
Lubriorb H	2 to 4 ms/g

PACKED SIZE

20 Kg

REGULATORY COMPLIANCE

• USP-NF • BP • EP

LubMag-W™

Co-processed Magnesium Stearate and Sodium Lauryl Sulfate

LUBRICANT

PRODUCT OVERVIEW

LubMag-W is an advance excipient system of co-processed Magnesium Stearate and Sodium Lauryl Sulphate that provides proven lubrication properties of Magnesium Stearate with superior wetting power of Sodium Lauryl Sulfate. This unique excipient system allows for better dispersion and flow properties during manufacturing processes.
LubMag-W conforms to stringent quality standards and helps meet regulatory requirements for pharmaceutical excipients.
LubMag-W extends our existing product portfolio of Lubricant and is produced according to a special production process.

KEY FEATURES

Particle shape

Engineered, more rounded or granular (controlled shape)

Particle size distribution

Narrow, optimized

Surface area

Optimized for uniform spread

Tendency to agglomerate

Low (stable dispersion due to co-processing)

Coverage on granules

Uniform coating around particles, reducing friction zones

Particle size distribution (Malvern)	
D10	Less than or equal to 25 micron
D50	Less than or equal to 50 micron
D90	Less than or equal to 125 micron

REGULATORY COMPLIANCE

- IH

Sucralose | Acesulfame K | Neotame

INTENSE SWEETENERS

PRODUCT OVERVIEW

KEY FEATURES

- Reduce Obesity
- Improve Dental Health
- Carbohydrate management for diabetics
- Tastes similar to sugars
- Smaller amount needed for same level of sweetening of sugar
- Enhances and extends flavor

ADVANTAGES

- Helps Reduce Calories
- Remains Stable Under High Temperatures
- Excellent Shelf Life
- Tastes Sweet and Clean
- Synergistic
- Does Not Promote Tooth Decay
- Useful in Diabetic Diets

REGULATORY COMPLIANCE

• USP-NF • BP • IP • EP

ProBlend®
Silicified Microcrystalline Cellulose

DILUENT

PRODUCT OVERVIEW



Revolutionizing Tablet Manufacturing with Unmatched Flowability and Strength

ProBlend is a co-processed Excipient composed of microcrystalline cellulose and colloidal silicon dioxide. It is specifically engineered to improve the compressibility, flow properties, and binding characteristics in tablet formulations.

Grades	Bulk Density (g/mL)
ProBlend® – LD	0.25-0.37
ProBlend® – HD	0.38-0.50
ProBlend®	0.45-0.75

KEY FEATURES

Superior Flowability
Ensures consistent feed in tablet presses.

Excellent Compactibility
Produces robust tablets with low friability.

Enhanced Uniformity
Promotes uniform distribution of APIs in blends.

Reduced Segregation
Prevents separation of powder blends during processing.

BENEFITS

- Facilitates high-speed manufacturing.
- Minimizes process downtime by reducing tablet defects.
- Compatible with a wide range of APIs and excipients.

APPLICATIONS

Direct Compression
Used in immediate-release and controlled-release tablets. Reduces the need for additional binders.

Capsule Filling
Improves bulk density and ensures uniform filling.

Granulation Processes
Enhances granule flow and strength in wet and dry granulation

REGULATORY COMPLIANCE

• USP-NF

Microlose™
Lactose Monohydrate & Microcrystalline Cellulose

DILUENT

PRODUCT OVERVIEW



MICROLOSE M25

Chemical Name : Lactose Monohydrate - 75%, Microcrystalline Cellulose - 25%

Pass Through Sieve 400# : NMT 15.0%
Pass Through Sieve 100# : 45.0% - 70.0%
Pass Through Sieve 60# : NLT 90.0%

BENEFITS

- Combination mitigates sensitivity of compression pressure on tablet hardness, disintegration, friability & dissolution.
- Optimum balance of cohesion and adhesion.
- Prevents sticking and heap formation tendency in dissolution testing.
- Mitigates sensitivity towards lubrication.
- It is a co-processed excipient having optimized combination of Lactose Monohydrate and Microcrystalline Cellulose, to make a balance to achieve superior compression properties and desired quality attributes.

REGULATORY COMPLIANCE

- IH

STARLOSE®

Starch & Lactose Monohydrate

DILUENT

PRODUCT OVERVIEW



Retained On Sieve 400# : NMT 85.0%
Retained On Sieve 100# : Between 35.0% - 65.0 %
Retained On Sieve 60# : NMT 20.0%

BENEFITS

- Starlose is a combination of Lactose Monohydrate and Maize Starch. Lactose is water loving and soluble in water, at high compression force it hampers disintegration. Starch has multifunction characters and act as binder as well as disintegrant.
- It provides improved tablet hardness, superior flowability and faster disintegration.
- It has excellent results in dry granulation, it imparts better hardness to the tablet after the second compression.
- Starlose has optimized composition of these two ingredients.

REGULATORY COMPLIANCE

- IH

Active Pharmaceutical Ingredient

- **Timolol Maleate**

  CAS No.: 26839-75-8

  Therapeutic Category: Anti-Glaucoma

  Regulatory Compliance: • USP-NF • BP • EP • IP

- **Salmeterol Xinafoate**

  CAS No.: 94749-08-3

  Therapeutic Category : Anti-Asthmatic

  Regulatory Compliance: • USP-NF • BP • EP • IP

- **Formoterol Fumarate**

  CAS No.: 43229-80-7

  Therapeutic Category : Anti-Asthmatic

  Regulatory Compliance: • USP-NF • BP • EP • IP

- **Modafinil**

  CAS No.: 68693-11-8

  Therapeutic Category : CNS Stimulant

  Regulatory Compliance: • USP-NF



Gellets-P®
Microcrystalline Cellulose Pellets

PELLETS FOR DRUG LOADING

PRODUCT OVERVIEW



Gellets-P are Microcrystalline Cellulose based spheres, which is neutral substrate for manufacturing of pellets.

- MUPS are important variant of solid oral dosage forms containing pellets (Microgranules) in tablets.
- Pellets in capsule is also another dosage form.
- Modi?ed released products can be developed by Pellets & MUPS technology.

KEY FEATURES

White or nearly white.

Better sphericity

Better processing, uniform layering on the surface which leads to accurate drug release.

Narrow particle size distribution

Better content uniformity, uniform particle size of finished microgranules, uniform surface area which yields to uniform / reproducible drug release.

Very low friability / Better hardness:

Its high mechanical strength makes it most suitable starting material for manufacturing of microgranules.

Non reactive substrate:

Suitable for direct drug layering.

Controlled swelling:

- Uniform drug release.
- Smell & odor free.
- Insoluble in non aqueous solvents.

PACKED SIZE

25 Kg

PHYSICAL PROPERTIES OF GELLETS-P®

GRADE	Particle Size (u)
14-18	1000-1400
18-20	840-1400
20-25	841-707
20-30	600-850
25-35	500-710
30-40	400-600
40-60	250-425
50-70	212-300
50-100	150-300
60-100	150-250

REGULATORY COMPLIANCE

• IH

Pharmaceutical Formulation Intermediates

A Pharmaceutical Formulation Intermediate (PFI) is a ready-to-compress or ready-to-fill blend of Active pharmaceutical ingredients (APIs) and Excipients, processed under GMP conditions and supplied as a finished blend. PFIs are commonly used in Direct Compression or simplified manufacturing processes.

Streamlining Pharma Manufacturing with Smart, Scalable PFI Solutions

Therapeutic Category		PFIs
Anti-Diabetic	High Volume Drugs	GranuMet - Metformin (IR / SR) 500 / 850 / 1000 mg
		Linagliptin 5 mg
		Metformin HCL and Sitagliptin
Cardiology	High Volume Drugs	GranuTel - Telmisartan (mono / combi) 20 / 40 / 80 mg
		GranuAml - Amlodipine (mono / combi) 2.5 / 5 mg
		Nebivolol 2.5 / 5 / 10 / 20 mg
GERD (Proton Pump Inhibiters)	Highly Unstable Drugs	GranuPan - Pantoprazole 20 / 40 mg
		GranuRab - Rabeprazole 10 / 20 mg
NSAID	High Volume Drugs	Paracetamol and Diclofenac
Diuretic	High Volume Drugs	Furosemide 20 / 40 / 80 mg

Pharmaceutical Formulation Intermediates

New Products

Product	% drug	Label claim	Tablet weight
Furosemide Granulesranules	25%	Each 80/160/320 mg of lubricated granules contains Furosemide 20/40/80 mg	80/160/ 320 mg
Linagliptin Granules	3.33%	Each 150 mg of lubricated granules contains Linagliptin 5 mg	150 mg
Nebivolol HCl Granules	6.38%	Each 78/156/313 mg of lubricated granules contains Nebivolol 5/10/20 mg	78/156/ 313 mg
Paracetamol & Diclofenac Granules	76.92% & 0.77%	Each 650 mg of lubricated granules contains Paracetamol 500 mg and Diclofenac 5 mg	650 mg
Metformin HCL & Sitagliptin Granules	83.33% & 4.17%	Each 1200 mg of lubricated granules contains Metformin HCL 1000 mg and Sitagliptin 50 mg	1200 mg

GANGWAL

Bringing Life To Formulations

Gangwal Healthcare Pvt. Ltd.

606, Quantum Tower, Rambagh Lane, Behind State Bank Of India, Malad (west), Mumbai - 400064, India

: +91 22417 03000 : www.gangwalhealthcare.com : info@gangwalhealthcare.com